Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma

H. Miles Prince, Madeleine Duvic, Ann Martin, Wolfram Sterry, Chalid Assaf, Yijun Sun, David Straus, Mark Acosta, Andres Negro-Vilar

Research output: Contribution to journalArticlepeer-review

168 Scopus citations

Abstract

Purpose: This phase III, placebo-controlled, randomized trial was designed to investigate efficacy and safety of two doses of denileukin diftitox (DD; DAB389-interleukin-2 [IL-2]), a recombinant fusion protein targeting IL-2 receptor - expressing malignant T lymphocytes, in patients with stage IA to III, CD25 assay - positive cutaneous T-cell lymphoma (CTCL), including the mycosis fungoides and Sézary syndrome forms of the disease, who had received up to three prior therapies. The primary end point was overall response rate (ORR). Patients and Methods: Patients (N = 144) with biopsy-confirmed, CD25 assay - positive CTCL were randomly assigned to DD 9 μg/kg/d (n = 45), DD 18 μg/kg/d (n = 55), or placebo infusions (n = 44), administered for 5 consecutive days every 3 weeks for up to eight cycles. Patients were monitored for drug efficacy, clinical benefit, and safety of DD. Results: ORR was 44% for all participants treated with DD (n = 100; 10% complete response [CR] and 34% partial response [PR]) compared with 15.9% for placebo-treated patients (2% CR and 13.6% PR). ORR was higher in the 18 μg/kg/d group versus the 9 μg/kg/d group (49.1% v 37.8%, respectively), and both doses were significantly superior to placebo. Progression-free survival (PFS) was significantly longer (median, > 2 years) for both DD doses compared with placebo (median, 124 days; P < .001). Rates of moderately severe and severe adverse events (AEs) were slightly higher in the DD groups, whereas moderate and mild AEs were similar to placebo. No statistical differences were observed for drug-related serious AEs. Conclusion: DD had a significant and durable effect on ORR and PFS with an acceptable safety profile in patients with early- and late-stage CTCL.

Original languageEnglish
Pages (from-to)1870-1877
Number of pages8
JournalJournal of Clinical Oncology
Volume28
Issue number11
DOIs
StatePublished - Apr 10 2010

Fingerprint

Dive into the research topics of 'Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma'. Together they form a unique fingerprint.

Cite this